← All organizations
Highest phase reached
Phase 2
First clinical trial
Jun 1, 2011Last known activity
Aug 29, 2023
Timeline
2010s
- Jun 1, 2011
Leap Therapeutics, Inc.— Founded
- Aug 29, 2016
MacroCure Ltd.— Acquired
Drugs by trial phase (21 distinct, 18 trials)
Phase 3 (0 own, 1 via acquisition)
Phase 2 (18 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinosarcoma
- Cholangiocarcinoma
- Endometrial Neoplasms
- Esophageal Neoplasms
- Lung Neoplasms
- Melanoma
- Mixed Tumor, Mullerian
- Multiple Myeloma
- Neoplasms
- Neoplasms, Plasma Cell
- Ovarian Neoplasms
- Prostatic Neoplasms
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Uterine Neoplasms
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (21)
- NCT04681248Study directorN/A—
- NCT04681248Lead sponsorN/A—
- NCT05761951CollaboratorPhase 2Aug 29, 2023
- NCT05480306Study directorPhase 2Aug 30, 2022
- NCT05480306Lead sponsorPhase 2Aug 30, 2022
- NCT04363801Lead sponsorPhase 2Jul 31, 2020
- NCT03818997CollaboratorPhase 2Aug 31, 2019
- NCT04057365CollaboratorPhase 2Aug 31, 2019
- NCT03861403Lead sponsorPhase 1/Phase 2May 15, 2019
- NCT03837353CollaboratorPhase 1/Phase 2Mar 30, 2019
- NCT03645980CollaboratorPhase 1/Phase 2Aug 31, 2018
- NCT03395080Lead sponsorPhase 2Feb 5, 2018
- NCT03395080Study directorPhase 2Feb 5, 2018
- NCT02628574Lead sponsorPhase 1Dec 1, 2015
- NCT02628574Study chairPhase 1Dec 1, 2015
Details
- Founded
- Cambridge, MA, US Jun 1, 2011
- Last known activity
- Aug 29, 2023